1
|
Bui TV, Picone DS, Schultz MG, Peng X, Black JA, Dwyer N, Roberts-Thomson P, Adams H, Chen CH, Cheng HM, Pucci G, Wang J, Goupil R, Sharman JE. Accuracy of cuff blood pressure and systolic blood pressure amplification. Hypertens Res 2023; 46:1961-1969. [PMID: 37217732 PMCID: PMC10404511 DOI: 10.1038/s41440-023-01311-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 03/23/2023] [Accepted: 04/12/2023] [Indexed: 05/24/2023]
Abstract
Automated cuff measured blood pressure (BP) is the global standard used for diagnosing hypertension, but there are concerns regarding the accuracy of the method. Individual variability in systolic BP (SBP) amplification from central (aorta) to peripheral (brachial) arteries could be related to the accuracy of cuff BP, but this has never been determined and was the aim of this study. Automated cuff BP and invasive brachial BP were recorded in 795 participants (74% male, aged 64 ± 11 years) receiving coronary angiography at five independent research sites (using seven different automated cuff BP devices). SBP amplification was recorded invasively by catheter and defined as brachial SBP minus aortic SBP. Compared with invasive brachial SBP, cuff SBP was significantly underestimated (130 ± 18 mmHg vs. 138 ± 22 mmHg, p < 0.001). The level of SBP amplification varied significantly among individuals (mean ± SD, 7.3 ± 9.1 mmHg) and was similar to level of difference between cuff and invasive brachial SBP (mean difference -7.6 ± 11.9 mmHg). SBP amplification explained most of the variance in accuracy of cuff SBP (R2 = 19%). The accuracy of cuff SBP was greatest among participants with the lowest SBP amplification (ptrend < 0.001). After cuff BP values were corrected for SBP amplification, there was a significant improvement in the mean difference from the intra-arterial standard (p < 0.0001) and in the accuracy of hypertension classification according to 2017 ACC/AHA guideline thresholds (p = 0.005). The level of SBP amplification is a critical factor associated with the accuracy of conventional automated cuff measured BP.
Collapse
Affiliation(s)
- Tan V Bui
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
| | - Dean S Picone
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
| | - Martin G Schultz
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
| | - Xiaoqing Peng
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - J Andrew Black
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
- Royal Hobart Hospital, Hobart, TAS, Australia
| | - Nathan Dwyer
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
- Royal Hobart Hospital, Hobart, TAS, Australia
| | - Philip Roberts-Thomson
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
- Royal Hobart Hospital, Hobart, TAS, Australia
| | - Heath Adams
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
- Royal Hobart Hospital, Hobart, TAS, Australia
| | - Chen-Huan Chen
- Department of Medicine, National Yang Ming Chiao Tung University, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Hao-Min Cheng
- Department of Medicine, National Yang Ming Chiao Tung University, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Giacomo Pucci
- Unit of Internal Medicine at Terni University Hospital, Department of Medicine, University of Perugia, Perugia, Italy
| | - Jiguang Wang
- Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Department of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Remi Goupil
- Hopital du Sacre-Coeur de Montreal, Universite de Montreal, Montreal, Canada
| | - James E Sharman
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
| |
Collapse
|
2
|
Rayner C, Adams H. Aortic stenosis and transcatheter aortic valve implantation in the elderly. Aust J Gen Pract 2023; 52:458-463. [PMID: 37423243 DOI: 10.31128/ajgp-08-22-6527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/11/2023]
Abstract
BACKGROUND Severe aortic stenosis (AS) is a condition that commonly affects elderly Australians. Once symptomatic, severe AS has a poor prognosis if untreated. Transcatheter aortic valve implantation (TAVI) is a percutaneous procedure that is now the recommended treatment for elderly patients with severe AS who are suitable for intervention. OBJECTIVE This article provides a contemporary review of the diagnosis and management of severe AS in the elderly. DISCUSSION Management options for severe AS include TAVI, surgical aortic valve replacement (SAVR), or medical/palliative therapy. In elderly adults, TAVI improves mortality, symptoms and quality of life compared with medical therapy, and is superior to SAVR. The decision regarding which management option is most appropriate for an individual patient is made using a collaborative multidisciplinary approach. General practitioners play key roles in providing information to risk stratify patients when considering intervention, caring for patients after the procedure and/or providing medical and palliative treatment for those deemed unsuitable for intervention.
Collapse
Affiliation(s)
- Clare Rayner
- BExSc, MD, MMED, Basic Physician Trainee, Royal Hobart Hospital, Hobart, Tas
| | - Heath Adams
- MBBS(Hons), BMedSci DipUKMP, GradDipClinLShip, FCSANZ, FRACP, Interventional Cardiologist, Royal Hobart Hospital, Hobart, Tas
| |
Collapse
|
3
|
Adams H, van de Garde EMW, Vugts DJ, Grutters JC, Oyen WJG, Keijsers RG. [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial. Eur J Nucl Med Mol Imaging 2023; 50:1929-1939. [PMID: 36826476 PMCID: PMC10199842 DOI: 10.1007/s00259-023-06143-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Accepted: 02/08/2023] [Indexed: 02/25/2023]
Abstract
INTRODUCTION Immune-mediated interstitial pneumonitis may be treated with anti-CD20 therapy after failure of conventional therapies. However, clinical response is variable. It was hypothesized that autoreactive CD20-positive cells may play an important role in this variability. This prospective study aims to elucidate if imaging of CD20-positive cells in the lungs allows prediction of the response to anti-CD20 treatment. METHODS Twenty-one patients with immune-mediated interstitial lung disease (ILD) with deteriorated pulmonary function received a dose of 1000 mg rituximab on day 1 and day 14 spiked with a tracer dose of radiolabeled [89Zr]-rituximab. PET/CT was performed on days 3 and 6. Standardized uptake values (SUV) were calculated as a measure for pulmonary CD20 expression. Based on pulmonary function tests (PFT), forced vital capacity (FVC), and diffusing capacity for carbon monoxide (DLCO), prior to and 6 months after treatment, patients were classified as responder (stable disease or improvement) or non-responder. RESULTS Fifteen patients (71%) were classified as responder. Pulmonary [89Zr]-rituximab PET SUVmean was significantly correlated with the change in FVC and DLCO (K = 0.49 and 0.56, respectively) when using target-to-background ratios, but not when using SUVmean alone. [89Zr]-rituximab SUVmean was significantly higher in responders than in non-responders (0.35 SD 0.09 vs. 0.23 SD 0.06; P = 0.02). CONCLUSION Rituximab treatment was effective in the majority of patients. As a higher pulmonary uptake of [89Zr]-rituximab correlated with improvement of PFT and treatment outcome, [89Zr]-rituximab PET imaging may serve as a potential predictive biomarker for anti-CD20 therapy. TRIAL REGISTRATION Clinicaltrials.gov identifier NCT02251964.
Collapse
Affiliation(s)
- H Adams
- Department of Nuclear Medicine, Groene Hart Hospital, Bleulandweg 10, 2803 HH, Gouda, the Netherlands.
- Department of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, the Netherlands.
| | - E M W van de Garde
- Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, the Netherlands
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands
| | - D J Vugts
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - J C Grutters
- Department of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, the Netherlands
- Division of Heart & Lung, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Wim J G Oyen
- Department of Biomedicals Sciences and Humanitas Clinical and Research Center, Department of Nuclear Medicine, Humanitas University, Milan, Italy
- Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, the Netherlands
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - R G Keijsers
- Department of Nuclear Medicine, St. Antonius Hospital, Nieuwegein, the Netherlands
| |
Collapse
|
4
|
Eaves S, Lees C, Jin D, Rayner C, Paleri S, Rowe S, Lee J, Hayat U, Adams H. Dedicated Next Day Discharge Post Minimalist TAVI: The Tasmanian Experience. Heart Lung Circ 2023; 32:232-239. [PMID: 36272953 DOI: 10.1016/j.hlc.2022.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 08/22/2022] [Accepted: 09/14/2022] [Indexed: 11/06/2022]
Abstract
OBJECTIVES To assess the safety, feasibility and independent predictors of next day discharge (NDD) in patients undergoing minimalist transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS) in a real-world Australian population. METHODS This single centre study reviewed 135 consecutive patients who underwent minimalist transfemoral TAVI from June 2020 to February 2022. Baseline demographics, procedural characteristic and outcomes were obtained. All patients were assessed by the local protocol for NDD. Patients were then divided into two groups: those who achieved next day discharge (NDD) and those requiring >1 overnight hospital stay. Univariate, bivariate and stepwise multivariate logistic regression modelling was used to identify the predictors of successful next day discharge. RESULTS The mean age of the cohort was 82.9±5.7 years with 62.3% patients male, the average STS score was 4.1±2.4. All 135 patients underwent a successful transfemoral TAVI procedure, with 131 (97%) receiving a balloon-expandable valve. Ninety-seven (97) (71.9%) patients achieved NDD. Thirty (30)-day outcomes were excellent with a 30-day mortality of 0.7%, transient ischaemic attack/cardiovascular accident (TIA/CVA) 1.5%, major vascular complication 1.5% and 11.4% need for permanent pacemaker (PPM). In patients not achieving NDD, the average length of stay (LOS) was 3.0 days. Baseline characteristics demonstrated pre-existing first degree atrioventricular (AV) block and right bundle branch block (RBBB) as statistically significant negative predictors of NDD on univariate analysis. Next day discharge was achievable in only 50% of patients who suffered any minor or major procedural complication (15/30). Stepwise multivariate logistic regression modelling demonstrated female gender (OR 3.094, 95% CI 1.141-8.391, p=0.026), smaller aortic valve area (AVA) (OR 48.265, 95% CI 2.269-102.6, p=0.013), the presence of diabetes mellitus (OR 0.594, 95% CI 0.356-0.991, p=0.046) and a longer procedure time (OR 0.960, 95% CI 0.935-0.986, p=0.002) as statistically significant negative predictors of NDD. In addition, there was no difference in 30-day readmission rates between the NDD and non-NDD cohort (7.2% vs 10.5%, p=0.386). CONCLUSION Next day discharge is safe and feasible in almost three quarters of patients undergoing minimalist TAVI for severe AS in a predominantly balloon expandable valve cohort, with a very low rate of 30-day readmission. NDD provides advantages for hospital efficiency and improved cost-effectiveness. Female gender, smaller AVA, the presence of diabetes mellitus and a longer procedure time were independent negative predictors of successful NDD.
Collapse
Affiliation(s)
- Scott Eaves
- Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia.
| | - Conor Lees
- Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia
| | - David Jin
- Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia
| | - Clare Rayner
- Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia
| | - Sarang Paleri
- Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia
| | - Stephanie Rowe
- Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia
| | - John Lee
- Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia
| | - Umair Hayat
- Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia
| | - Heath Adams
- Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia; Menzies Research Institute, University of Tasmania, Hobart, Tas, Australia
| |
Collapse
|
5
|
Melero I, Grande Pulido E, De Miguel Luken M, Johnson M, Bauman J, Moreno Garcia V, Walter A, Adams H, Türeci Ö, Russo G, Sahin U, Steinberg J, Ahmadi T, Felip E. 175P Safety and preliminary efficacy of GEN1042 (DuoBody-CD40x4-1BB) combination therapy in patients with advanced solid tumors. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
6
|
Bui TV, Picone DS, Schultz MG, Armstrong MK, Peng X, Black JA, Dwyer N, Roberts-Thomson P, Adams H, Hughes AD, Sharman JE. Comparison between cuff-based and invasive systolic blood pressure amplification. J Hypertens 2022; 40:2037-2044. [PMID: 36052526 PMCID: PMC7614121 DOI: 10.1097/hjh.0000000000003228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Accurate measurement of central blood pressure (BP) using upper arm cuff-based methods is associated with several factors, including determining the level of systolic BP (SBP) amplification. This study aimed to determine the agreement between cuff-based and invasively measured SBP amplification. METHODS Patients undergoing coronary angiography had invasive SBP amplification (brachial SBP - central SBP) measured simultaneously with cuff-based SBP amplification using a commercially available central BP device (device 1: Sphygmocor Xcel; n = 171, 70% men, 60 ± 10 years) and a now superseded model of a central BP device (device 2: Uscom BP+; n = 52, 83% men, 62 ± 10 years). RESULTS Mean difference (±2SD, limits of agreement) between cuff-based and invasive SBP amplification was 4 mmHg (-12, +20 mmHg, P < 0.001) for device 1 and -2 mmHg (-14, +10 mmHg, P = 0.10) for device 2. Both devices systematically overestimated SBP amplification at lower levels and underestimated at higher levels of invasive SBP amplification, but with stronger bias for device 1 (r = -0.68 vs. r = -0.52; Z = 2.72; P = 0.008). Concordance of cuff-based and invasive SBP amplification across quartiles of invasive SBP amplification was low, particularly in the lowest and highest quartiles. The root mean square errors from regression between cuff-based central SBP and brachial SBP were significantly lower (indicating less variability) than from invasive regression models (P < 0.001). CONCLUSIONS Irrespective of the difference from invasive measurements, cuff-based estimates of SBP amplification showed evidence of proportional systematic bias and had less individual variability. These observations could provide insights on how to improve the performance of cuff-based central BP.
Collapse
Affiliation(s)
- Tan V Bui
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
| | - Dean S Picone
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
| | - Martin G Schultz
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
| | - Matthew K Armstrong
- Department of Health and Human Physiology, University of Iowa, Iowa City, Iowa, USA
| | - Xiaoqing Peng
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - J Andrew Black
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
- Royal Hobart Hospital, Hobart, Australia
| | - Nathan Dwyer
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
- Royal Hobart Hospital, Hobart, Australia
| | - Philip Roberts-Thomson
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
- Royal Hobart Hospital, Hobart, Australia
| | - Heath Adams
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
- Royal Hobart Hospital, Hobart, Australia
| | - Alun D Hughes
- MRC Unit for Lifelong Health and Ageing at UCL, Institute of Cardiovascular Sciences, University College London, London, UK
| | - James E Sharman
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
| |
Collapse
|
7
|
Dawson LP, Quinn S, Tong D, Boyle A, Hamilton-Craig C, Adams H, Layland J. Colchicine and quality of life in patients with acute coronary syndromes: Results from the COPS randomized trial. Cardiovasc Revasc Med 2022; 44:53-59. [PMID: 35739010 DOI: 10.1016/j.carrev.2022.06.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Revised: 06/14/2022] [Accepted: 06/15/2022] [Indexed: 11/03/2022]
Abstract
BACKGROUND Recent data suggest that colchicine may reduce cardiovascular events among patients presenting with acute coronary syndromes. This sub-study of the Australian COPS trial aimed to assess whether colchicine affects health status outcomes. METHODS Health status was assessed at baseline and 12-months using the EuroQol-5 Dimension 5-level (EQ-5D-5L) score and the full 19-question Seattle Angina Questionnaire (SAQ). Data were available for 786 patients (388 randomized to colchicine, 398 to placebo). RESULTS Baseline characteristics were well matched between groups; mean age was 60.1 (SD 14.8) years, and 20 % were female. Baseline health status scores were impaired, and most parameters demonstrated significant improvement from baseline to 12-months (EQ-5D-5L Visual Analogue Score [VAS] 69.3 to 77.7; SAQ angina frequency score 83.0 to 95.3, both p < 0.001). No significant differences in adjusted mean score change among any of the EQ-5D-5L or SAQ dimensions were observed between treatment groups in either intention-to-treat or per-protocol analysis. There were borderline interactions in EQ-5D-5L scores for those with previous MI vs not, and in SAQ scores for those with obesity vs not. In categorical analysis using observed data, patients treated with colchicine were more likely to have clinically significant improvement in physical limitation score over the period (36 % improved vs. 28 %, p < 0.05). Baseline health status scores were not associated with the primary endpoint at 12 months. CONCLUSIONS Treatment with colchicine did not appear to affect change in measures of health status following acute coronary syndromes, but it did lead to a greater likelihood of improvement in physical limitation scores. TRIAL REGISTRATION ACTRN, ACTRN12615000861550. Registered 18/08/2015, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368973.
Collapse
Affiliation(s)
- Luke P Dawson
- Department of Cardiology, Peninsula Health, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Stephen Quinn
- Swinburne University of Technology, Department of Health Science and Biostatistics, Hawthorn, Victoria, Australia
| | - David Tong
- Department of Cardiology, Peninsula Health, Melbourne, Victoria, Australia; St Vincent's Hospital, Melbourne, Victoria, Australia
| | - Andrew Boyle
- School of Medicine and Public Health, University of Newcastle, New South Wales, Australia
| | - Christian Hamilton-Craig
- The Prince Charles Hospital, Brisbane, Queensland, Australia; School of Medicine, Griffith University, Australia
| | - Heath Adams
- Royal Hobart Hospital, Hobart, Tasmania, Australia
| | - Jamie Layland
- Department of Cardiology, Peninsula Health, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia.
| |
Collapse
|
8
|
Almåsbak H, Hartberg R, Meås H, Zaliauskiene L, Vebø H, Kjær S, Bernstrøm K, Økern G, Rasmussen J, Gjølberg D, Nilssen N, Mevatne S, Landsverk O, Kern J, Hermans P, Klijs E, Adams H, Merino A, Åmellem Ø, Sierkstra L, Zynda E, Herreng TH. Process Development and Manufacturing: NOVEL PLATFORM OF ACTIVE-RELEASE MAGNETIC BEAD TECHNOLOGY FOR THE ENHANCEMENT OF T CELL THERAPIES. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00451-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Rowe S, Lees C, Lee J, Eaves S, Paleri S, Jin D, Rayner C, Hayat U, Adams H. Is Pacing Always Permanent Following TAVI? A Single-Centre Experience. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Tong DC, Bloom JE, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, Sriamareswaran R, Htun NM, Wilson W, Stub D, van Gaal W, Howes L, Yeap A, Yip B, Wu S, Perera P, Collins N, Yong A, Bhindi R, Whitbourn R, Lee A, Premaratne M, Asrress K, Freeman M, Amerena J, Layland J. Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial. Circulation 2021; 144:1584-1586. [PMID: 34748393 DOI: 10.1161/circulationaha.121.054610] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- David C Tong
- St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia (D.C.T., R.W., J.L.)
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
| | - Jason E Bloom
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
- Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia (J.E.B., D.S.)
- The Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (J.E.B.)
| | - Stephen Quinn
- Swinburne University of Technology, Department of Health Science and Biostatistics, Hawthorn, Victoria, Australia (S.Q.)
| | - Arthur Nasis
- MonashHeart, Monash Health, Clayton, Victoria, Australia (A.N.)
| | - Chin Hiew
- Barwon Health - University Hospital Geelong, Victoria, Australia (C.H., J.A.)
| | | | - Heath Adams
- Royal Hobart Hospital, Hobart, Tasmania, Australia (P.R.-T., H.A.)
| | - Rumes Sriamareswaran
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
| | - Nay M Htun
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
| | - William Wilson
- Royal Melbourne Hospital, Parkville, Victoria, Australia (W.W.)
| | - Dion Stub
- Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia (J.E.B., D.S.)
- Western Health, St Albans, Victoria, Australia (D.S.)
| | | | - Laurie Howes
- Gold Coast University Hospital, Southport, Queensland, Australia (L.H.)
| | - Allysha Yeap
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
| | - Brian Yip
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
| | - Sam Wu
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
| | - Padeepa Perera
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
| | - Nicholas Collins
- John Hunter Hospital, New Lambton Heights, New South Wales, Australia (N.C.)
| | - Andy Yong
- Concord Repatriation General Hospital, New South Wales, Australia (A. Yong)
| | - Ravinay Bhindi
- Royal North Shore Hospital, St Leonards, New South Wales, Australia (R.B.)
| | - Robert Whitbourn
- St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia (D.C.T., R.W., J.L.)
| | - Astin Lee
- Wollongong Hospital, New South Wales, Australia (A.L.)
| | - Manuja Premaratne
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
| | - Kaleab Asrress
- Bankstown-Lidcombe Hospital, New South Wales, Australia (K.A.)
| | | | - John Amerena
- Barwon Health - University Hospital Geelong, Victoria, Australia (C.H., J.A.)
| | - Jamie Layland
- St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia (D.C.T., R.W., J.L.)
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., J.E.B., R.S., N.M.H., A. Yeap, B.Y., S.W., P.P., M.P., J.L.)
- Peninsula Clinical School, Central Clinical School, Monash University, Victoria, Australia (J.L.)
| |
Collapse
|
11
|
Dawson L, Quinn S, Tong D, Boyle A, Hamilton-Craig C, Adams H, Layland J. Colchicine and quality of life in patients with acute coronary syndromes: results from the COPS randomized trial. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Recent data suggest that colchicine may reduce cardiovascular events among patients presenting with acute coronary syndromes. This sub-study of the Australian COPS trial aimed to assess whether colchicine affects health status outcomes.
Methods
Health status was assessed at baseline and 12-months using the EuroQol-5 Dimension 5-level (EQ-5D-5L) score and the full 19-question Seattle Angina Questionnaire (SAQ). Data were available for 786 patients (388 randomized to colchicine, 398 to placebo).
Results
Baseline characteristics were well matched between groups; mean age was 60.1 (SD 14.8) years, and 20% were female. Baseline health status scores were impaired, and most parameters demonstrated significant improvement from baseline to 12-months (EQ-5D-5L Visual Analogue Score [VAS] 69.3 to 77.7; SAQ angina frequency score 83.0 to 95.3, both p<0.001). No significant differences in adjusted mean score change among any of the EQ-5D-5L or SAQ dimensions were observed between treatment groups in either intention-to-treat or per-protocol analysis. There were borderline interactions in EQ-5D-5L scores for those with previous MI vs not, and in SAQ scores for those with obesity vs not. In categorical analysis using observed data, patients treated with colchicine were more likely to have clinically significant improvement in physical limitation score over the period (36% improved vs. 28%, P<0.05). Baseline health status scores were not associated with the primary endpoint at 12 months.
Conclusions
Treatment with colchicine did not appear to affect change in measures of health status following acute coronary syndromes, but it did lead to a greater likelihood of improvement in physical limitation scores.
Funding Acknowledgement
Type of funding sources: Public hospital(s). Main funding source(s): Peninsula Health, Monash University
Collapse
Affiliation(s)
- L Dawson
- Royal Melbourne Hospital, Melbourne, Australia
| | - S Quinn
- Swinburne University of Technology, Department of Health Science and Biostatistics, Melbourne, Australia
| | - D Tong
- Peninsula Health, Department of Cardiology, Melbourne, Australia
| | - A Boyle
- University of Newcastle, Newcastle, Australia
| | | | - H Adams
- Royal Hobart Hospital, Hobart, Australia
| | - J Layland
- Peninsula Health, Department of Cardiology, Frankston, Australia
| |
Collapse
|
12
|
Stav-Noraas T, Kjær S, Alfsnes K, Økern G, Bernstroem K, Gjolberg D, Klijs E, Wielders C, Adams H, de Rooij J, Almasbak H, Holt Herreng T, Hermans P, Sierkstra L, Amellem O. Leveraging single-domain antibodies and magnetic bead technology to improve manufacturing of T-cells for cell therapies. Cytotherapy 2021. [DOI: 10.1016/s1465324921004175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Bell AR, Wrathall DJ, Mueller V, Chen J, Oppenheimer M, Hauer M, Adams H, Kulp S, Clark PU, Fussell E, Magliocca N, Xiao T, Gilmore EA, Abel K, Call M, Slangen ABA. Migration towards Bangladesh coastlines projected to increase with sea-level rise through 2100. Environ Res Lett 2021; 16:024045. [PMID: 36034333 PMCID: PMC9415774 DOI: 10.1088/1748-9326/abdc5b] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
To date, projections of human migration induced by sea-level change (SLC) largely suggest large-scale displacement away from vulnerable coastlines. However, results from our model of Bangladesh suggest counterintuitively that people will continue to migrate toward the vulnerable coastline irrespective of the flooding amplified by future SLC under all emissions scenarios until the end of this century. We developed an empirically calibrated agent-based model of household migration decision-making that captures the multi-faceted push, pull and mooring influences on migration at a household scale. We then exposed ~4800 000 simulated migrants to 871 scenarios of projected 21st-century coastal flooding under future emissions pathways. Our model does not predict flooding impacts great enough to drive populations away from coastlines in any of the scenarios. One reason is that while flooding does accelerate a transition from agricultural to non-agricultural income opportunities, livelihood alternatives are most abundant in coastal cities. At the same time, some coastal populations are unable to migrate, as flood losses accumulate and reduce the set of livelihood alternatives (so-called 'trapped' populations). However, even when we increased access to credit, a commonly-proposed policy lever for incentivizing migration in the face of climate risk, we found that the number of immobile agents actually rose. These findings imply that instead of a straightforward relationship between displacement and migration, projections need to consider the multiple constraints on, and preferences for, mobility. Our model demonstrates that decision-makers seeking to affect migration outcomes around SLC would do well to consider individual-level adaptive behaviors and motivations that evolve through time, as well as the potential for unintended behavioral responses.
Collapse
Affiliation(s)
- A R Bell
- Department of Earth and Environment, Boston University, Boston, MA 02215, United States of America
- Department of Environmental Studies, New York University, New York, NY 10012, United States of America
| | - D J Wrathall
- College of Earth, Ocean and Atmospheric Sciences, Oregon State University, Corvallis, OR 97331-5503, United States of America
| | - V Mueller
- School of Politics and Global Studies, Arizona State University, Tempe, AZ 85287-3902, United States of America
- International Food Policy Research Institute, Washington, DC 20005, United States of America
| | - J Chen
- Department of Agricultural, Environmental, and Development Economics, The Ohio State University, Columbus, OH 43210, United States of America
| | - M Oppenheimer
- School of Public and International Affairs and Department of Geosciences, Princeton University, Princeton, NJ 08544-1013, United States of America
| | - M Hauer
- Department of Sociology, Florida State University, Tallahassee, FL 32306, United States of America
| | - H Adams
- Department of Geography, King's College London, London WC2R 2LS, United Kingdom
| | - S Kulp
- Climate Central, Princeton, NJ 08542, United States of America
| | - P U Clark
- College of Earth, Ocean and Atmospheric Sciences, Oregon State University, Corvallis, OR 97331-5503, United States of America
- School of Geography and Environmental Sciences, University of Ulster, Coleraine, Northern Ireland BT52 1SA, United Kingdom
| | - E Fussell
- Population Studies and Training Center and the Institute at Brown on Environment and Society, Brown University, Providence, RI 02912, United States of America
| | - N Magliocca
- Department of Geography, University of Alabama, Tuscaloosa, AL 35401, United States of America
| | - T Xiao
- School of Public and International Affairs and Department of Geosciences, Princeton University, Princeton, NJ 08544-1013, United States of America
| | - E A Gilmore
- Department of International Development, Community and Environment, Clark University, Worcester, MA 01610-1477, United States of America
| | - K Abel
- College of Earth, Ocean and Atmospheric Sciences, Oregon State University, Corvallis, OR 97331-5503, United States of America
| | - M Call
- USAID, Washington, DC, United States of America
| | - A B A Slangen
- Department of Estuarine and Delta Systems, NIOZ Royal Netherlands Institute for Sea Research, Yerseke 4401 NT, The Netherlands
| |
Collapse
|
14
|
Jin D, Lees C, MacIntyre P, Dwyer N, Hayat U, Adams H. The Tasmanian TAVI Service: Initial Experience and Outcomes. Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.06.509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, Sriamareswaran R, Htun NM, Wilson W, Stub D, van Gaal W, Howes L, Collins N, Yong A, Bhindi R, Whitbourn R, Lee A, Hengel C, Asrress K, Freeman M, Amerena J, Wilson A, Layland J. Colchicine in Patients With Acute Coronary Syndrome. Circulation 2020; 142:1890-1900. [DOI: 10.1161/circulationaha.120.050771] [Citation(s) in RCA: 127] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Background:
Inflammation plays a crucial role in clinical manifestations and complications of acute coronary syndromes (ACS). Colchicine, a commonly used treatment for gout, has recently emerged as a novel therapeutic option in cardiovascular medicine owing to its anti-inflammatory properties. We sought to determine the potential usefulness of colchicine treatment in patients with ACS.
Methods:
This was a multicenter, randomized, double-blind, placebo-controlled trial involving 17 hospitals in Australia that provide acute cardiac care service. Eligible participants were adults (18–85 years) who presented with ACS and had evidence of coronary artery disease on coronary angiography managed with either percutaneous coronary intervention or medical therapy. Patients were assigned to receive either colchicine (0.5 mg twice daily for the first month, then 0.5 mg daily for 11 months) or placebo, in addition to standard secondary prevention pharmacotherapy, and were followed up for a minimum of 12 months. The primary outcome was a composite of all-cause mortality, ACS, ischemia-driven (unplanned) urgent revascularization, and noncardioembolic ischemic stroke in a time to event analysis.
Results:
A total of 795 patients were recruited between December 2015 and September 2018 (mean age, 59.8±10.3 years; 21% female), with 396 assigned to the colchicine group and 399 to the placebo group. Over the 12-month follow-up, there were 24 events in the colchicine group compared with 38 events in the placebo group (
P
=0.09, log-rank). There was a higher rate of total death (8 versus 1;
P
=0.017, log-rank) and, in particular, noncardiovascular death in the colchicine group (5 versus 0;
P
=0.024, log-rank). The rates of reported adverse effects were not different (colchicine 23.0% versus placebo 24.3%), and they were predominantly gastrointestinal symptoms (colchicine, 23.0% versus placebo, 20.8%).
Conclusions:
The addition of colchicine to standard medical therapy did not significantly affect cardiovascular outcomes at 12 months in patients with ACS and was associated with a higher rate of mortality.
Registration:
URL:
https://www.anzctr.org.au
; Unique identifier: ACTRN12615000861550.
Collapse
Affiliation(s)
- David C. Tong
- St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia (D.C.T., R.W., A.W., J.L.)
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., R.S., N.M.H., J.L.)
| | - Stephen Quinn
- Swinburne University of Technology, Department of Health Science and Biostatistics, Hawthorn, Victoria, Australia (S.Q.)
| | - Arthur Nasis
- MonashHeart, Monash Health, Clayton, Victoria, Australia (A.N.)
| | - Chin Hiew
- Barwon Health, University Hospital Geelong, Victoria, Australia (C.H., J.A.)
| | | | - Heath Adams
- Royal Hobart Hospital, Tasmania, Australia (P.R.-T., H.A.)
| | - Rumes Sriamareswaran
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., R.S., N.M.H., J.L.)
| | - Nay M. Htun
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., R.S., N.M.H., J.L.)
| | - William Wilson
- Royal Melbourne Hospital, Parkville, Victoria, Australia (W.W.)
| | - Dion Stub
- Western Health, St Albans, Victoria, Australia (D.S.)
| | | | - Laurie Howes
- Gold Coast University Hospital, Southport, Queensland, Australia (L.H.)
| | - Nicholas Collins
- John Hunter Hospital, New Lambton Heights, New South Wales, Australia (N.C.)
| | - Andy Yong
- Concord Repatriation General Hospital, New South Wales, Australia (A.Y.)
| | - Ravinay Bhindi
- Royal North Shore Hospital, St Leonards, New South Wales, Australia (R.B.)
| | - Robert Whitbourn
- St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia (D.C.T., R.W., A.W., J.L.)
| | - Astin Lee
- Wollongong Hospital, New South Wales, Australia (A.L.)
| | - Chris Hengel
- Ballarat Health Services, Victoria, Australia (C.H.)
| | - Kaleab Asrress
- Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia (K.A.)
| | | | - John Amerena
- Barwon Health, University Hospital Geelong, Victoria, Australia (C.H., J.A.)
| | - Andrew Wilson
- St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia (D.C.T., R.W., A.W., J.L.)
| | - Jamie Layland
- St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia (D.C.T., R.W., A.W., J.L.)
- Cardiology, Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (D.C.T., R.S., N.M.H., J.L.)
- Peninsula Clinical School, Central Clinical School, Monash University, Victoria, Australia (J.L.)
| |
Collapse
|
16
|
Tham JLM, Adams H, Paleri S, Wright C, Dimitriou J, Newcomb A, MacIsaac AI, Whitbourn RJ, Palmer SC. Clinical outcomes of self-expandable vs. balloon-expandable TAVI for severe aortic stenosis. Acta Cardiol 2020; 75:218-225. [PMID: 30931804 DOI: 10.1080/00015385.2019.1572959] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is an established therapy for patients with severe aortic stenosis (AS). There is limited data exploring differences in outcomes post-TAVI SEV vs. BEV. This study compared procedural success and 30-d clinical outcomes self-expandable valves (SEV), vs. balloon-expandable valves (BEV) for patients with severe AS.Methods: Retrospective analysis was undertaken of patients receiving TAVI at St Vincent's Hospital, Melbourne between August 2009 and May 2018. The primary endpoints included procedural success, clinical outcomes and complication rates at 30-d.Results: Out of 151 patients undergoing TAVI, 70 received (46.3%) SEV (Medtronic CoreValve & Evolut-R) and 81 (53.6%) BEV (Edwards SAPIEN-XT & S3). The mean Society of Thoracic Surgery (STS) risk score did not differ between the groups, SEV (83.6 ± 4.9 years, STS 4.4 ± 3.8) compared to BEV (82.3 ± 5.8 years, STS 4.9 ± 4.9). Procedural success was similar SEV 67 (95.7%) vs. BEV 78 (96.3%). Rates of ≥ moderate paravalvular aortic regurgitation (PAR) at 30-d were significantly higher in SEV compared to BEV (6.7 vs. 0.0%; p = .02). SEV patients had higher rates of pacemaker insertion (36.4 vs. 9.5%; p = .001) and stroke rates (12.4 vs. 1.4%; p = .04) compared to BEV patients. The difference in 30-d mortality between the two groups was similar (SEV 4.6% vs. BEV 1.3%; p = .23).Conclusions: This real-world retrospective analysis demonstrates higher rates of ≥ moderate PAR, stroke and pacemaker insertion with SEV compared to BEV at 30 d post-TAVI for severe symptomatic AS.
Collapse
Affiliation(s)
| | - Heath Adams
- Department of Cardiology, St Vincent’s Hospital Melbourne, Fitzroy, Australia
- School of Medicine, University of Tasmania, Hobart, Australia
| | - Sarang Paleri
- Department of Cardiology, St Vincent’s Hospital Melbourne, Fitzroy, Australia
| | - Christine Wright
- Department of Cardiology, St Vincent’s Hospital Melbourne, Fitzroy, Australia
| | - Jim Dimitriou
- Department of Cardiac Surgery, St Vincent’s Hospital Melbourne, Fitzroy, Australia
| | - Andrew Newcomb
- Department of Cardiac Surgery, St Vincent’s Hospital Melbourne, Fitzroy, Australia
| | - Andrew I. MacIsaac
- Department of Medicine, University of Melbourne, Fitzroy, Australia
- Department of Cardiology, St Vincent’s Hospital Melbourne, Fitzroy, Australia
| | - Robert J. Whitbourn
- Department of Medicine, University of Melbourne, Fitzroy, Australia
- Department of Cardiology, St Vincent’s Hospital Melbourne, Fitzroy, Australia
| | - Sonny C. Palmer
- Department of Medicine, University of Melbourne, Fitzroy, Australia
- Department of Cardiology, St Vincent’s Hospital Melbourne, Fitzroy, Australia
| |
Collapse
|
17
|
Adams H, Roberts-Thomson R, Patterson T, Prendergast B, Redwood S. The Low-Risk TAVI Trials for Severe Aortic Stenosis: Future Implications for Australian and New Zealand Heart Teams. Heart Lung Circ 2020; 29:657-661. [PMID: 32115372 DOI: 10.1016/j.hlc.2020.01.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 01/16/2020] [Indexed: 12/21/2022]
Affiliation(s)
- Heath Adams
- Department of Cardiology, St Thomas' Hospital, London, UK; Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia; School of Medicine, University of Tasmania, Hobart, Tas, Australia.
| | - Ross Roberts-Thomson
- Department of Cardiology, St Thomas' Hospital, London, UK; Department of Cardiology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Tiffany Patterson
- Department of Cardiology, St Thomas' Hospital, London, UK; Cardiovascular Department, King's College London, London, UK
| | | | - Simon Redwood
- Department of Cardiology, St Thomas' Hospital, London, UK; Cardiovascular Department, King's College London, London, UK
| |
Collapse
|
18
|
Patterson T, Rajani R, Esposito G, Allen C, Adams H, Prendergast B, Young C, Redwood S. Transcatheter Aortic Valve-in-Valve Implantation Complicated by Aorto-Right Ventricular Fistula. JACC Case Rep 2020; 2:309-311. [PMID: 33215164 PMCID: PMC7658332 DOI: 10.1016/j.jaccas.2019.11.086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 11/21/2019] [Accepted: 11/22/2019] [Indexed: 11/30/2022]
Abstract
We describe the case of a degenerative, sutureless bioprosthetic valve (BPV) with deformation and stent infolding in a patient with elevated surgical risk. Following discussion among the heart team, balloon valve fracture was performed to facilitate deployment of an aortic valve-in-valve transcatheter heart valve. Post-procedural imaging demonstrated BPV frame protrusion and contained annular rupture, which required operative intervention. (Level of Difficulty: Intermediate.).
Collapse
Affiliation(s)
- Tiffany Patterson
- Cardiovascular Division, The Rayne Institute British Heart Foundation Centre of Research Excellence, King's College London, St. Thomas’ Hospital, London, United Kingdom
| | - Ronak Rajani
- Cardiothoracic Department, Guy’s and St. Thomas’ National Health Service Foundation Trust, London, United Kingdom
| | - Giulia Esposito
- Cardiovascular Division, The Rayne Institute British Heart Foundation Centre of Research Excellence, King's College London, St. Thomas’ Hospital, London, United Kingdom
| | - Christopher Allen
- Cardiovascular Division, The Rayne Institute British Heart Foundation Centre of Research Excellence, King's College London, St. Thomas’ Hospital, London, United Kingdom
| | - Heath Adams
- Cardiothoracic Department, Guy’s and St. Thomas’ National Health Service Foundation Trust, London, United Kingdom
| | - Bernard Prendergast
- Cardiothoracic Department, Guy’s and St. Thomas’ National Health Service Foundation Trust, London, United Kingdom
| | - Christopher Young
- Cardiothoracic Department, Guy’s and St. Thomas’ National Health Service Foundation Trust, London, United Kingdom
| | - Simon Redwood
- Cardiovascular Division, The Rayne Institute British Heart Foundation Centre of Research Excellence, King's College London, St. Thomas’ Hospital, London, United Kingdom
| |
Collapse
|
19
|
Affiliation(s)
- David Jin
- St Vincent's Hospital Melbourne Melbourne VIC
- Medicine at St Vincent's HospitalUniversity of Melbourne Melbourne VIC
| | - Heath Adams
- St Vincent's Hospital Melbourne Melbourne VIC
- University of Tasmania Hobart TAS
| | | | | | - Sonny Palmer
- St Vincent's Hospital Melbourne Melbourne VIC
- Medicine at St Vincent's HospitalUniversity of Melbourne Melbourne VIC
| |
Collapse
|
20
|
Ha FJ, Adams H, Palmer S. Device closure for patent foramen ovale in patients with cryptogenic stroke: a paradigm in evidence. Med J Aust 2019; 211:343-344.e1. [DOI: 10.5694/mja2.50341] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
| | - Heath Adams
- St Vincent's Hospital Melbourne Melbourne VIC
| | | |
Collapse
|
21
|
Patterson T, Adams H, Allen C, Rajani R, Prendergast B, Redwood S. Indirect Annuloplasty to Treat Functional Mitral Regurgitation: Current Results and Future Perspectives. Front Cardiovasc Med 2019; 6:60. [PMID: 31165074 PMCID: PMC6536087 DOI: 10.3389/fcvm.2019.00060] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Accepted: 04/24/2019] [Indexed: 11/29/2022] Open
Abstract
The incidence of mitral regurgitation (MR) is approximately 1.7% in the developed world, and this increases to more than 10% in patients aged over 75 years. Functional (or secondary) mitral regurgitation (FMR) is defined as poor leaflet coaptation and tethering secondary to either ischemic or non-ischemic left ventricular (LV) dysfunction and dilatation. FMR is more common than degenerative (or primary) MR and is associated with significantly worse outcomes in patients with heart failure, post myocardial infarction and following coronary artery bypass graft surgery. Patients with severe degenerative MR have excellent outcomes with surgical repair, however the benefits of surgery in FMR are less clear. Although annuloplasty is associated with a lower operative mortality compared to replacement, the recurrence rate of mitral regurgitation is high in patients with FMR and neither surgical repair or replacement have been shown to reduce hospitalisation or death in FMR. Furthermore, nearly half of patients are deemed too high risk for surgery and therefore most patients are managed conservatively and there remains an unmet clinical need. Transcatheter mitral valve interventions are an emerging alternative for those at high surgical risk. This mini review focuses on indirect mitral annuloplasty: anatomical considerations, patient selection, current devices, implantation techniques and the associated clinical outcome data.
Collapse
Affiliation(s)
- Tiffany Patterson
- Cardiovascular, King's College London, St. Thomas Hospital, London, United Kingdom
| | - Heath Adams
- Cardiovascular, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Christopher Allen
- Cardiovascular, King's College London, St. Thomas Hospital, London, United Kingdom
| | - Ronak Rajani
- Cardiovascular, King's College London, St. Thomas Hospital, London, United Kingdom
| | - Bernard Prendergast
- Cardiovascular, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Simon Redwood
- Cardiovascular, King's College London, St. Thomas Hospital, London, United Kingdom
| |
Collapse
|
22
|
Brennan AP, Martin W, Adams H, Yii M. Impact of the Cox-Maze IV Procedure on Left Atrial Mechanical Function. Heart Lung Circ 2018; 28:1835-1840. [PMID: 30528812 DOI: 10.1016/j.hlc.2018.11.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 08/13/2018] [Accepted: 11/16/2018] [Indexed: 11/25/2022]
Abstract
BACKGROUND The Cox-Maze IV procedure is a proven surgical treatment for atrial fibrillation (AF). Previous studies on the procedure and its effect on left atrial mechanical function have yielded mixed results. METHODS Sixty-four (64) patients underwent Cox-Maze IV at St Vincent's Hospital, Melbourne between March 2010 and May 2016. Baseline characteristics were collected and outcomes assessed including rhythm analysis. Preoperative and postoperative transthoracic echocardiograms were reviewed. RESULTS Fifty-seven (57) patients had complete follow-up with all clinical measures collected. The mean age was 71.1±10.2years, 63% being male. Fifty-eight per cent (58%) (33/57) of patients were in AF and 42% (24/57) in sinus rhythm (SR) at preoperative transthoracic echocardiography. Follow-up postoperative transthoracic echocardiography was performed at a mean of 2.3±1.9years. Nineteen (19) patients with a history of paroxysmal AF were in SR both preoperatively and postoperatively. In these patients, there was a significant decrease in Mitral A wave 0.63±0.28m/s (pre-op) vs 0.47±0.29m/s (post-op), p=0.044. There was a significant decrease in left ventricular ejection fraction (LVEF) postoperatively 64.2±9.7% vs 55.0±12.9%, p=0.005. At follow-up, 28% (16/57) were in AF, 61% (35/57) in SR, and 11% (6/57) in a paced rhythm. In a multivariate analysis, predictors of AF recurrence included higher LA volumes (p=0.042) and younger age at surgery p=0.030. Preoperative AF, sex and LVEF had no impact on AF recurrence. CONCLUSIONS The Cox-Maze IV procedure, while effective in converting patients to sinus rhythm, may reduce left atrial mechanical function in patients with paroxysmal AF.
Collapse
Affiliation(s)
| | | | - Heath Adams
- St Vincent's Hospital, Melbourne, Victoria, Australia
| | - Michael Yii
- St Vincent's Hospital, Melbourne, Victoria, Australia
| |
Collapse
|
23
|
Lents CA, Thorson JF, Adams H, Petersen SL, Prezotto L, Berry ED, Nonneman DJ. 394 Nutritional Regulation of LH Secretion in Gilts: Hypothalamic Expression of Kisspeptin and Neurokinin B. J Anim Sci 2018. [DOI: 10.1093/jas/sky073.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- C A Lents
- USDA, ARS, U.S. Meat Animal Research Center, Clay Center, NE
| | - J F Thorson
- USDA, ARS, U.S. Meat Animal Research Center, Clay Center, NE
| | - H Adams
- University of Massachusetts, Amherst, MA
| | | | | | - E D Berry
- USDA, ARS, U.S. Meat Animal Research Center, Clay Center, NE
| | - D J Nonneman
- USDA, ARS, U.S. Meat Animal Research Center, Clay Center, NE
| |
Collapse
|
24
|
Paleri S, Tham J, Jin D, Wright C, Baradi A, Adams H, MacIsaac A, Whitbourn R, Palmer S. Incidence and Predictors of Vascular Complications in Transcatheter Aortic Valve Implantation. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
25
|
Tham J, Paleri S, Wright C, Adams H, MacIsaac A, Whitbourn R, Palmer S. A Comparison of Clinical Outcomes Between Self-Expanding and Balloon-Expanding Transcatheter Aortic Valve Devices. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
26
|
Chingle MP, Osagie IA, Adams H, Gwomson D, Emeribe N, Zoakah AI. Risk perception of hepatitis B infection and uptake of hepatitis B vaccine among students of tertiary institution in Jos. Ann Afr Med 2017; 16:59-64. [PMID: 28469118 PMCID: PMC5452710 DOI: 10.4103/aam.aam_49_16] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Background: Hepatitis B virus (HBV) Infection is endemic in Nigeria. Healthcare students are more vulnerable because of direct contact with patients’ body fluids and blood. Risk perception of HBV and HB vaccine uptake are also poor. The aim of this study was to assess the level of risk perception of hepatitis B infection, and uptake of the HBV vaccine, between medical and other students of the University of Jos. Methods: A comparative cross sectional study was conducted among 1,200 students of the departments of Medicine, Nursing sciences and Public Administration, University of Jos (400 from each arm) using a pretested self-administered questionnaire. A five point Likert scoring system was used to assess risk perception. Data was analyzed using SPSS version 20. A P -value of <0.05 was considered significant. Results: Awareness on HB vaccine prevention was high (88.4%) among University of Jos students. Awareness was similar among medical and nursing students (36.2% and 36.0% respectively) but lower among public administration student (27.8%), P < 0.001. The overall risk perception was 76.8%. This was also similar for medical and nursing students (40.7% and 40.1% respectively), but lower for public administration students (9.1%), P < 0.001. Risk perception is 5x higher among medical students compared to public administration students (OR = 5.22, 95% CI = 2.19 – 12.93; P < 0.001). The uptake of full dose HB vaccine was 60.2%, 20.6% and 15.1% for medical, nursing and public administration students respectively. Medical students are 4x more likely to go for HB vaccination compared with public administration students (OR=3.62; 95% CI=2.39 – 5.48; P < 0.001). Conclusions: Awareness and risk perception on HBV infection are high among University of Jos students, but uptake of HB vaccine is low. Findings are worst for non-health students.
Collapse
Affiliation(s)
- M P Chingle
- Department of Community Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
| | - I A Osagie
- Department of Community Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
| | - H Adams
- Department of Community Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
| | - D Gwomson
- Department of Community Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
| | - N Emeribe
- Department of Community Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
| | - A I Zoakah
- Department of Community Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
| |
Collapse
|
27
|
Trakarnwijitr I, Li B, Adams H, Layland J, Garlick J, Wilson A. Age modulates the relationship between platelet-to-lymphocyte ratio and coronary artery disease. Int J Cardiol 2017; 248:349-354. [DOI: 10.1016/j.ijcard.2017.06.127] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2017] [Revised: 06/20/2017] [Accepted: 06/30/2017] [Indexed: 01/31/2023]
|
28
|
Jiang J, Adams H, Lange M, Siemann S, Feldkamp M, Schulze S, Froehler S, Yaung S, Yao L, Balasubramanyam A, Tikoo N, Achenbach H, Krügel R, Palma J, Rosenthal A. OA 10.06 Longitudinal Mutation Monitoring in Plasma by Deep Sequencing as a Potential Predictor of Disease Progression in NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
Abstract
Contemporary treatment modalities for malignancy including radiation therapy have led to improved survival. However treatment related complications manifesting later in life including cardiovascular disease has led to survivors exhibiting a lower long term survival rate, when compared to age matched controls. This narrative review will discuss the pathophysiology, risk factors, clinical presentation, management and preventative techniques related to radiotherapy-induced cardiotoxicity.
Collapse
|
30
|
Adams H, Paratz E, Somaratne J, Layland J, Burns A, Palmer S, MacIsaac A, Whitbourn R. Different patients, different outcomes: A case-control study of spontaneous coronary artery dissection versus acute coronary syndrome. J Interv Cardiol 2017; 31:41-47. [PMID: 28940292 DOI: 10.1111/joic.12447] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2017] [Revised: 08/28/2017] [Accepted: 08/29/2017] [Indexed: 11/28/2022] Open
Abstract
INTRODUCTION There is progressive interest worldwide in spontaneous coronary artery dissection (SCAD). To identify a SCAD cohort and compare risk factors, presentation, and management outcomes compared to acute coronary syndrome (ACS) matched controls. METHODS Retrospective analysis was performed from 2000 to 2015. Clinical data included a neuropsychiatric history, with management and clinical outcomes assessed at 12 months. Patients were matched on a 1:3 case-control basis according to type of ACS. Twenty-two SCAD patients were matched to 66 controls by ACS type (ST-elevation myocardial infarction 45%, Non-ST-elevation myocardial infarction 41%, unstable angina 14%). RESULTS The SCAD group were more likely female (77.3% vs 19.7%, P < 0.0001), of younger age (48.7 ± 10.7 years vs 61.3 ± 10.6 years, P < 0.0001) with no cases of diabetes (0% vs 33.3%, P = 0.002), compared to controls. SCAD patients had a high prevalence of anxiety, depression or previous neuropsychiatric history (52.4% SCAD vs 1.5% ACS, P < 0.0001). A conservative revascularization strategy with stenting was performed in a minority of SCAD patients (13.6% SCAD vs 83.3% ACS, P < 0.0001), with no significant difference in cumulative major adverse cardiac or cerebrovascular events (MACCE) of death, stroke, re-admission, or repeat angiography rates between both groups (13.6% SCAD vs 27.3% ACS P = NS). CONCLUSION SCAD affects young females with a paucity of cardiovascular risk factors. The major risk factor for SCAD was a history of anxiety, depression, or neuropsychiatric illness. A conservative approach to SCAD revascularization led to similar MACCE when compared to ACS controls undergoing guideline revascularization at 12 months.
Collapse
Affiliation(s)
- Heath Adams
- Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia
| | - Elizabeth Paratz
- Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia
| | | | - Jamie Layland
- Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia
| | - Andrew Burns
- Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia
| | - Sonny Palmer
- Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia
| | - Andrew MacIsaac
- Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia
| | - Robert Whitbourn
- Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia
| |
Collapse
|
31
|
Trakarnwijitr I, Li B, Adams H, Layland J, Garlick J, Wilson A. P6231Platelet-to-lymphocyte ratio is a marker of multivessel coronary artery disease in high risk older patients. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Nguyen A, Adams H, Gin J, Yap N, Wilson-O’brien A, Garlick J, Wilson AM. Total serum bilirubin is an independent risk factor for coronary artery disease in men compared to women. Acta Cardiol 2017. [DOI: 10.1080/ac.71.6.3178187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Anke Nguyen
- St Vincent’s Hospital Melbourne, Cardiology Department, Australia
| | - Heath Adams
- St Vincent’s Hospital Melbourne, Cardiology Department, Australia
| | | | - Natalie Yap
- St Vincent’s Hospital Melbourne, Cardiology Department, Australia
| | | | | | - Andrew M. Wilson
- St Vincent’s Hospital Melbourne, Cardiology Department, Australia
- University of Melbourne, Australia
| |
Collapse
|
33
|
Weigel K, Pralle RS, Adams H, Cho K, Do C, White H. Prediction of whole‐genome risk for selection and management of hyperketonemia in Holstein dairy cattle. J Anim Breed Genet 2017; 134:275-285. [DOI: 10.1111/jbg.12259] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Accepted: 01/15/2017] [Indexed: 12/21/2022]
Affiliation(s)
- K.A. Weigel
- Department of Dairy Science University of Wisconsin Madison WI USA
| | - R. S. Pralle
- Department of Dairy Science University of Wisconsin Madison WI USA
| | - H. Adams
- MOFA International Center for Biotechnology Cooperative Resources International Mt Horeb WI USA
| | - K. Cho
- Division of Animal Breeding and Genetics National Institute of Animal Science Cheonan Korea
| | - C. Do
- Division of Animal and Dairy Science Chungnam National University DaejeonKorea
| | - H.M. White
- Department of Dairy Science University of Wisconsin Madison WI USA
| |
Collapse
|
34
|
Carriere JS, Thibault P, Adams H, Milioto M, Ditto B, Sullivan MJL. Expectancies mediate the relationship between perceived injustice and return to work following whiplash injury: A 1-year prospective study. Eur J Pain 2017; 21:1234-1242. [PMID: 28493479 DOI: 10.1002/ejp.1023] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/24/2017] [Indexed: 11/11/2022]
Abstract
BACKGROUND Emerging evidence suggests that perceived injustice is a risk factor for work disability in individuals with whiplash injury. At present, however, little is known about the processes by which perceived injustice impacts on return to work. The purpose of this study was to examine whether expectancies mediated the relationship between perceived injustice and return to work in patients with whiplash injury. METHOD One hundred and fifty-two individuals (81 men, 71 women) with a primary diagnosis of whiplash injury completed self-report measures of pain intensity, perceived injustice and return-to-work expectancies following admission to a rehabilitation programme. Work status was assessed 1 year after discharge. RESULTS Consistent with previous research, high scores on a measure of perceived injustice were associated with prolonged work disability. Results indicated that high perceptions of injustice were associated with low return-to-work expectancies. Causal mediation analyses revealed that expectancies fully mediated the relationship between perceived injustice and return to work. CONCLUSION The findings suggest that intervention techniques designed to target expectancies could improve return-to-work outcomes in patients with whiplash injury. Discussion addresses the processes by which expectancies might impact on return-to-work outcomes and the manner in which negative return-to-work expectancies might be modified through intervention. SIGNIFICANCE The study confirms that expectancies are the mechanism through which perceived injustice impacts return to work following whiplash injury. The findings suggest that interventions designed to specifically target return-to-work expectancies might improve rehabilitation outcomes in patients with whiplash injury.
Collapse
Affiliation(s)
- J S Carriere
- Department of Psychology, McGill University, Montreal, QC, Canada
| | - P Thibault
- Department of Psychology, McGill University, Montreal, QC, Canada
| | - H Adams
- Faculty of Health and Behavioural Sciences, University of Queensland, Herston, Qld, Australia
| | - M Milioto
- CERE - Clinique d'Evaluation et de Readaptation de l'Est, Montreal, QC, Canada
| | - B Ditto
- Department of Psychology, McGill University, Montreal, QC, Canada
| | - M J L Sullivan
- Faculty of Health and Behavioural Sciences, University of Queensland, Herston, Qld, Australia
| |
Collapse
|
35
|
Martin W, Galligan J, Adams H, Palmer S. Lactobacillus acidophilus , A Probiotic or a Problem? A Case of Endocarditis Associated with Probiotic Use. Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.586] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Adams H, Newcomb A, Wright C, Burns A, MacIsaac A, Whitbourn R, Palmer S. Balloon Aortic Valvuloplasty Is a Safe and Effective Temporising Therapy Prior to Aortic Valve Intervention for Severe Symptomatic Aortic Stenosis. Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Li X, Reeder AT, Torri F, Adams H, Jones S. Mechanistic investigations of the asymmetric hydrosilylation of ketimines with trichlorosilane reveals a dual activation model and an organocatalyst with enhanced efficiency. Org Biomol Chem 2017; 15:2422-2435. [DOI: 10.1039/c6ob02537d] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Mechanistic investigations of a catalyst used for the asymmetric hydrosilylation have revealed a ‘dual activation’ model and catalyst that maintains its performance at 0.01 mol% loading.
Collapse
Affiliation(s)
- X. Li
- Department of Chemistry
- University of Sheffield
- Sheffield
- UK S3 7HF
| | - A. T. Reeder
- Department of Chemistry
- University of Sheffield
- Sheffield
- UK S3 7HF
| | - F. Torri
- Department of Chemistry
- University of Sheffield
- Sheffield
- UK S3 7HF
| | - H. Adams
- Department of Chemistry
- University of Sheffield
- Sheffield
- UK S3 7HF
| | - S. Jones
- Department of Chemistry
- University of Sheffield
- Sheffield
- UK S3 7HF
| |
Collapse
|
38
|
Adams H, Cunliffe T, Azari M, Graham A, Galligan J, Black A, Dwyer N, Roberts-Thomson P. Ticagrelor Cessation Rates and Risk Factors Post Acute Coronary Syndrome. Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Nguyen A, Adams H, Gin J, Yap N, Wilson-O'Brien A, Garlick J, Wilson AM. Total serum bilirubin is an independent risk factor for coronary artery disease in men compared to women. Acta Cardiol 2016; 71:685-689. [PMID: 27920456 DOI: 10.2143/ac.71.6.3178187] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
40
|
Prior DL, Adams H, Williams TJ. Update on pharmacotherapy for pulmonary hypertension. Med J Aust 2016; 205:271-6. [DOI: 10.5694/mja16.00468] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Accepted: 07/07/2016] [Indexed: 12/14/2022]
|
41
|
Trakarnwijitr I, Li B, Adams H, Layland J, Garlick J, Wilson A. Elevated neutrophils, monocytes and white cell counts in patients with myocardial infarction compared with stable coronary artery disease. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
42
|
Martin W, Adams H, Darby J, Burns A, Mariani J. Propionibacterium Acnes Associated With Dense Pericardial Calcification and Constriction. Heart Lung Circ 2016. [DOI: 10.1016/j.hlc.2016.06.647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
43
|
Adams H, Paratz E, Somaratne J, Layland J, Whitbourn R. A Comparison of Outcomes in Spontaneous Coronary Artery Dissection Compared to Matched Acute Coronary Syndrome Controls. Heart Lung Circ 2016. [DOI: 10.1016/j.hlc.2016.06.060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
Li B, Trakarnwijitr I, Adams H, Layland J, Garlick J, Wilson A. PS046 High Lymphocytes and Low Mean Corpuscular Volume are Associated with Diabetes, Triglyceride-to-High-Density Lipoprotein Ratio and Metabolic Syndrome, in Patients at High Risk of Coronary Artery Disease. Glob Heart 2016. [DOI: 10.1016/j.gheart.2016.03.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
45
|
Trakarnwijitr I, Li B, Adams H, Layland J, Garlick J, Wilson A. PS130 Elevated Neutrophils, Monocytes and White Cell Counts in Patients With Myocardial Infarction Compared With Stable Coronary Artery Disease. Glob Heart 2016. [DOI: 10.1016/j.gheart.2016.03.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
46
|
Bawa RA, Gautier FM, Adams H, Meijer AJHM, Jones S. Evaluating hydrogen bonding control in the diastereoselective Diels-Alder reactions of 9-(2-aminoethyl)-anthracene derivatives. Org Biomol Chem 2015; 13:10569-77. [PMID: 26340318 DOI: 10.1039/c5ob01343g] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Several 9-(2-aminoethyl)anthracene derivatives were prepared with different nitrogen substitutents including alkyl, acetamide, trifluoroacaeamide and t-butyl carbamate. The selectivity in Diels-Alder cyclodaddition reaction with N-methyl maleimide was evaluated through single crystal X-ray analysis of the products. Models for the change in selectivity with hydrogen bond acceptor are proposed, supported by DFT level calculations.
Collapse
Affiliation(s)
- R A Bawa
- Department of Chemistry, University of Sheffield, Dainton Building, Brook Hill, Sheffield, S3 7HF, UK.
| | | | | | | | | |
Collapse
|
47
|
Matheus Carnevali PB, Rohrssen M, Williams MR, Michaud AB, Adams H, Berisford D, Love GD, Priscu JC, Rassuchine O, Hand KP, Murray AE. Methane sources in arctic thermokarst lake sediments on the North Slope of Alaska. Geobiology 2015; 13:181-197. [PMID: 25612141 DOI: 10.1111/gbi.12124] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Accepted: 12/19/2014] [Indexed: 06/04/2023]
Abstract
The permafrost on the North Slope of Alaska is densely populated by shallow lakes that result from thermokarst erosion. These lakes release methane (CH4 ) derived from a combination of ancient thermogenic pools and contemporary biogenic production. Despite the potential importance of CH4 as a greenhouse gas, the contribution of biogenic CH4 production in arctic thermokarst lakes in Alaska is not currently well understood. To further advance our knowledge of CH4 dynamics in these lakes, we focused our study on (i) the potential for microbial CH4 production in lake sediments, (ii) the role of sediment geochemistry in controlling biogenic CH4 production, and (iii) the temperature dependence of this process. Sediment cores were collected from one site in Siqlukaq Lake and two sites in Sukok Lake in late October to early November. Analyses of pore water geochemistry, sedimentary organic matter and lipid biomarkers, stable carbon isotopes, results from CH4 production experiments, and copy number of a methanogenic pathway-specific gene (mcrA) indicated the existence of different sources of CH4 in each of the lakes chosen for the study. Analysis of this integrated data set revealed that there is biological CH4 production in Siqlukaq at moderate levels, while the very low levels of CH4 detected in Sukok had a mixed origin, with little to no biological CH4 production. Furthermore, methanogenic archaea exhibited temperature-dependent use of in situ substrates for methanogenesis, and the amount of CH4 produced was directly related to the amount of labile organic matter in the sediments. This study constitutes an important first step in better understanding the actual contribution of biogenic CH4 from thermokarst lakes on the coastal plain of Alaska to the current CH4 budgets.
Collapse
Affiliation(s)
- P B Matheus Carnevali
- Division of Earth and Ecosystem Sciences, Desert Research Institute, Reno, NV, USA; Department of Biochemistry and Molecular Biology, University of Nevada, Reno, NV, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Davies G, Armstrong N, Bis JC, Bressler J, Chouraki V, Giddaluru S, Hofer E, Ibrahim-Verbaas CA, Kirin M, Lahti J, van der Lee SJ, Le Hellard S, Liu T, Marioni RE, Oldmeadow C, Postmus I, Smith AV, Smith JA, Thalamuthu A, Thomson R, Vitart V, Wang J, Yu L, Zgaga L, Zhao W, Boxall R, Harris SE, Hill WD, Liewald DC, Luciano M, Adams H, Ames D, Amin N, Amouyel P, Assareh AA, Au R, Becker JT, Beiser A, Berr C, Bertram L, Boerwinkle E, Buckley BM, Campbell H, Corley J, De Jager PL, Dufouil C, Eriksson JG, Espeseth T, Faul JD, Ford I, Scotland G, Gottesman RF, Griswold ME, Gudnason V, Harris TB, Heiss G, Hofman A, Holliday EG, Huffman J, Kardia SLR, Kochan N, Knopman DS, Kwok JB, Lambert JC, Lee T, Li G, Li SC, Loitfelder M, Lopez OL, Lundervold AJ, Lundqvist A, Mather KA, Mirza SS, Nyberg L, Oostra BA, Palotie A, Papenberg G, Pattie A, Petrovic K, Polasek O, Psaty BM, Redmond P, Reppermund S, Rotter JI, Schmidt H, Schuur M, Schofield PW, Scott RJ, Steen VM, Stott DJ, van Swieten JC, Taylor KD, Trollor J, Trompet S, Uitterlinden AG, Weinstein G, Widen E, Windham BG, Jukema JW, Wright AF, Wright MJ, Yang Q, Amieva H, Attia JR, Bennett DA, Brodaty H, de Craen AJM, Hayward C, Ikram MA, Lindenberger U, Nilsson LG, Porteous DJ, Räikkönen K, Reinvang I, Rudan I, Sachdev PS, Schmidt R, Schofield PR, Srikanth V, Starr JM, Turner ST, Weir DR, Wilson JF, van Duijn C, Launer L, Fitzpatrick AL, Seshadri S, Mosley TH, Deary IJ. Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53949). Mol Psychiatry 2015; 20:183-92. [PMID: 25644384 PMCID: PMC4356746 DOI: 10.1038/mp.2014.188] [Citation(s) in RCA: 260] [Impact Index Per Article: 28.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Revised: 11/11/2014] [Accepted: 11/24/2014] [Indexed: 01/14/2023]
Abstract
General cognitive function is substantially heritable across the human life course from adolescence to old age. We investigated the genetic contribution to variation in this important, health- and well-being-related trait in middle-aged and older adults. We conducted a meta-analysis of genome-wide association studies of 31 cohorts (N=53,949) in which the participants had undertaken multiple, diverse cognitive tests. A general cognitive function phenotype was tested for, and created in each cohort by principal component analysis. We report 13 genome-wide significant single-nucleotide polymorphism (SNP) associations in three genomic regions, 6q16.1, 14q12 and 19q13.32 (best SNP and closest gene, respectively: rs10457441, P=3.93 × 10(-9), MIR2113; rs17522122, P=2.55 × 10(-8), AKAP6; rs10119, P=5.67 × 10(-9), APOE/TOMM40). We report one gene-based significant association with the HMGN1 gene located on chromosome 21 (P=1 × 10(-6)). These genes have previously been associated with neuropsychiatric phenotypes. Meta-analysis results are consistent with a polygenic model of inheritance. To estimate SNP-based heritability, the genome-wide complex trait analysis procedure was applied to two large cohorts, the Atherosclerosis Risk in Communities Study (N=6617) and the Health and Retirement Study (N=5976). The proportion of phenotypic variation accounted for by all genotyped common SNPs was 29% (s.e.=5%) and 28% (s.e.=7%), respectively. Using polygenic prediction analysis, ~1.2% of the variance in general cognitive function was predicted in the Generation Scotland cohort (N=5487; P=1.5 × 10(-17)). In hypothesis-driven tests, there was significant association between general cognitive function and four genes previously associated with Alzheimer's disease: TOMM40, APOE, ABCG1 and MEF2C.
Collapse
Affiliation(s)
- G Davies
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK,Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - N Armstrong
- School of Mathematics and Statistics, University of Sydney, Sydney, NSW, Australia
| | - J C Bis
- Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA
| | - J Bressler
- Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - V Chouraki
- Inserm-UMR744, Institut Pasteur de Lille, Unité d'Epidémiologie et de Santé Publique, Lille, France,Department of Neurology, Boston University School of Medicine, Boston, MA, USA
| | - S Giddaluru
- K.G. Jebsen Centre for Psychosis Research and the Norwegian Centre for Mental Disorders Research (NORMENT), Department of Clinical Science, University of Bergen, Bergen, Norway,Dr Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
| | - E Hofer
- Department of Neurology, Medical University of Graz, Graz, Austria,Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
| | - C A Ibrahim-Verbaas
- Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands,Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - M Kirin
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
| | - J Lahti
- Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland,Folkhälsan Research Centre, Helsinki, Finland
| | - S J van der Lee
- Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - S Le Hellard
- K.G. Jebsen Centre for Psychosis Research and the Norwegian Centre for Mental Disorders Research (NORMENT), Department of Clinical Science, University of Bergen, Bergen, Norway,Dr Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
| | - T Liu
- Max Planck Institute for Human Development, Berlin, Germany,Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - R E Marioni
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK,Medical Genetics Section, University of Edinburgh Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK,Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - C Oldmeadow
- Hunter Medical Research Institute and Faculty of Health, University of Newcastle, Newcastle, NSW, Australia
| | - I Postmus
- Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands,Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands
| | - A V Smith
- Icelandic Heart Association, Kopavogur, Iceland,University of Iceland, Reykjavik, Iceland
| | - J A Smith
- Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA
| | - A Thalamuthu
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
| | - R Thomson
- Menzies Research Institute, Hobart, Tasmania
| | - V Vitart
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - J Wang
- Framingham Heart Study, Framingham, MA, USA,Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
| | - L Yu
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA
| | - L Zgaga
- Department of Public Health and Primary Care, Trinity College Dublin, Dublin, Ireland,Andrija Stampar School of Public Health, Medical School, University of Zagreb, Zagreb, Croatia
| | - W Zhao
- Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA
| | - R Boxall
- Medical Genetics Section, University of Edinburgh Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK
| | - S E Harris
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK,Medical Genetics Section, University of Edinburgh Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK
| | - W D Hill
- Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - D C Liewald
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
| | - M Luciano
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK,Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - H Adams
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands,Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands
| | - D Ames
- National Ageing Research Institute, Royal Melbourne Hospital, Melbourne, VIC, Australia,Academic Unit for Psychiatry of Old Age, St George's Hospital, University of Melbourne, Kew, Australia
| | - N Amin
- Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands,Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands
| | - P Amouyel
- Inserm-UMR744, Institut Pasteur de Lille, Unité d'Epidémiologie et de Santé Publique, Lille, France
| | - A A Assareh
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
| | - R Au
- Department of Neurology, Boston University School of Medicine, Boston, MA, USA,Framingham Heart Study, Framingham, MA, USA
| | - J T Becker
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA,Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA,Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA
| | - A Beiser
- Department of Neurology, Boston University School of Medicine, Boston, MA, USA,Framingham Heart Study, Framingham, MA, USA
| | - C Berr
- Inserm, U106, Montpellier, France,Université Montpellier I, Montpellier, France
| | - L Bertram
- Max Planck Institute for Molecular Genetics, Berlin, Germany,Faculty of Medicine, School of Public Health, Imperial College, London, UK
| | - E Boerwinkle
- Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA,Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas Health Science Center at Houston, Houston, TX, USA,Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA
| | - B M Buckley
- Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland
| | - H Campbell
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
| | - J Corley
- Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - P L De Jager
- Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA,Harvard Medical School, Boston, MA, USA,Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA
| | - C Dufouil
- Inserm U708, Neuroepidemiology, Paris, France,Inserm U897, Université Bordeaux Segalen, Bordeaux, France
| | - J G Eriksson
- Folkhälsan Research Centre, Helsinki, Finland,National Institute for Health and Welfare, Helsinki, Finland,Department of General Practice and Primary health Care, University of Helsinki, Helsinki, Finland,Unit of General Practice, Helsinki University Central Hospital, Helsinki, Finland
| | - T Espeseth
- K.G. Jebsen Centre for Psychosis Research, Norwegian Centre For Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Department of Psychology, University of Oslo, Oslo, Norway
| | - J D Faul
- Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA
| | - I Ford
- Robertson Center for Biostatistics, Glasgow, UK
| | - Generation Scotland
- Generation Scotland, University of Edinburgh Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK
| | - R F Gottesman
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - M E Griswold
- Center of Biostatistics and Bioinformatics, University of Mississippi Medical Center, Jackson, MS, USA
| | - V Gudnason
- Icelandic Heart Association, Kopavogur, Iceland,University of Iceland, Reykjavik, Iceland
| | - T B Harris
- Intramural Research Program National Institutes on Aging, National Institutes of Health, Bethesda, MD, USA
| | - G Heiss
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA
| | - A Hofman
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands,Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands
| | - E G Holliday
- Hunter Medical Research Institute and Faculty of Health, University of Newcastle, Newcastle, NSW, Australia
| | - J Huffman
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - S L R Kardia
- Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA
| | - N Kochan
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, NSW, Australia
| | - D S Knopman
- Department of Neurology, Mayo Clinic, Rochester, MN, USA
| | - J B Kwok
- Neuroscience Research Australia, Randwick, NSW, Australia,School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
| | - J-C Lambert
- Inserm-UMR744, Institut Pasteur de Lille, Unité d'Epidémiologie et de Santé Publique, Lille, France
| | - T Lee
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, NSW, Australia
| | - G Li
- Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA
| | - S-C Li
- Max Planck Institute for Human Development, Berlin, Germany,Technische Universität Dresden, Dresden, Germany
| | - M Loitfelder
- Department of Neurology, Medical University of Graz, Graz, Austria
| | - O L Lopez
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
| | - A J Lundervold
- Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway,Kavli Research Centre for Aging and Dementia, Haraldsplass Deaconess Hospital, Bergen, Norway,K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen, Bergen, Norway
| | - A Lundqvist
- Umeå Center for Functional Brain Imaging (UFBI), Umeå University, Umeå, Sweden
| | - K A Mather
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
| | - S S Mirza
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands,Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands
| | - L Nyberg
- Umeå Center for Functional Brain Imaging (UFBI), Umeå University, Umeå, Sweden,Department of Radiation Sciences, Umeå University, Umeå, Sweden,Department of Integrative Medical Biology, Umeå University, Umeå, Sweden
| | - B A Oostra
- Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - A Palotie
- Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK,Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland,Department of Medical Genetics, University of Helsinki and University Central Hospital, Helsinki, Finland
| | - G Papenberg
- Max Planck Institute for Human Development, Berlin, Germany,Karolinska Institutet, Aging Research Center, Stockholm University, Stockholm, Sweden
| | - A Pattie
- Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - K Petrovic
- Department of Neurology, Medical University of Graz, Graz, Austria
| | - O Polasek
- Faculty of Medicine, Department of Public Health, University of Split, Split, Croatia
| | - B M Psaty
- Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA,Deparment of Epidemiology, University of Washington, Seattle, WA, USA,Deparment of Health Services, University of Washington, Seattle, WA, USA,Group Health Research Unit, Group Health Cooperative, Seattle, WA, USA
| | - P Redmond
- Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - S Reppermund
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
| | - J I Rotter
- Institute for Translational Genomics and Population Sciences Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, CA, USA,Division of Genetic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Los Angeles, CA, USA
| | - H Schmidt
- Department of Neurology, Medical University of Graz, Graz, Austria,Centre for Molecular Medicine, Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria
| | - M Schuur
- Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands,Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - P W Schofield
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - R J Scott
- Hunter Medical Research Institute and Faculty of Health, University of Newcastle, Newcastle, NSW, Australia
| | - V M Steen
- K.G. Jebsen Centre for Psychosis Research and the Norwegian Centre for Mental Disorders Research (NORMENT), Department of Clinical Science, University of Bergen, Bergen, Norway,Dr Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
| | - D J Stott
- Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
| | - J C van Swieten
- Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - K D Taylor
- Institute for Translational Genomics and Population Sciences Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, CA, USA,Department of Pediatrics, Harbor-UCLA Medical Center, Los Angeles, CA, USA
| | - J Trollor
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Department of Developmental Disability Neuropsychiatry, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
| | - S Trompet
- Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands,Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
| | - A G Uitterlinden
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands,Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands,Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - G Weinstein
- Department of Neurology, Boston University School of Medicine, Boston, MA, USA,Framingham Heart Study, Framingham, MA, USA
| | - E Widen
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - B G Windham
- Division of Geriatrics, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA
| | - J W Jukema
- Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands,Durrer Center for Cardiogenetic Research, Amsterdam, The Netherlands,Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands
| | - A F Wright
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - M J Wright
- Neuroimaging Genetics Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Q Yang
- Framingham Heart Study, Framingham, MA, USA,Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
| | - H Amieva
- Inserm U897, Université Bordeaux Segalen, Bordeaux, France
| | - J R Attia
- Hunter Medical Research Institute and Faculty of Health, University of Newcastle, Newcastle, NSW, Australia
| | - D A Bennett
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA
| | - H Brodaty
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Dementia Collaborative Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - A J M de Craen
- Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands,Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands
| | - C Hayward
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - M A Ikram
- Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands,Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands,Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands,Department of Radiology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - U Lindenberger
- Max Planck Institute for Human Development, Berlin, Germany
| | - L-G Nilsson
- ARC, Karolinska Institutet, Stockholm and UFBI, Umeå University, Umeå, Sweden
| | - D J Porteous
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK,Medical Genetics Section, University of Edinburgh Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK,Generation Scotland, University of Edinburgh Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK
| | - K Räikkönen
- Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland
| | - I Reinvang
- Department of Psychology, University of Oslo, Oslo, Norway
| | - I Rudan
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
| | - P S Sachdev
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, NSW, Australia
| | - R Schmidt
- Department of Neurology, Medical University of Graz, Graz, Austria
| | - P R Schofield
- Neuroscience Research Australia, Sydney, NSW, Australia,Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - V Srikanth
- Menzies Research Institute, Hobart, Tasmania,Stroke and Ageing Research, Medicine, Southern Clinical School, Monash University, Melbourne, VIC, Australia
| | - J M Starr
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK,Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK
| | - S T Turner
- Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - D R Weir
- Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA
| | - J F Wilson
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
| | - C van Duijn
- Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands,Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands
| | - L Launer
- Intramural Research Program National Institutes on Aging, National Institutes of Health, Bethesda, MD, USA
| | - A L Fitzpatrick
- Deparment of Epidemiology, University of Washington, Seattle, WA, USA,Department of Global Health, University of Washington, Seattle, WA, USA
| | - S Seshadri
- Department of Neurology, Boston University School of Medicine, Boston, MA, USA,Framingham Heart Study, Framingham, MA, USA
| | - T H Mosley
- Division of Geriatrics, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA
| | - I J Deary
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK,Department of Psychology, University of Edinburgh, Edinburgh, UK,Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ, Scotland, UK. E-mail:
| |
Collapse
|
49
|
|
50
|
Hann N, Yap N, Gin J, Nguyen A, Adams H, Wilson A. Candidates for novel lipid-lowering therapies: persistently high on-treatment LDL-C in STEMI and NSTEMI patients. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|